AF6敲除上调胆汁酸生成促进CXCL14介导的HCC抗肿瘤免疫
该研究在二乙基亚硝胺诱导的Af6敲除小鼠肝癌模型中,发现Af6缺失增加初级胆汁酸水平,改变肠道菌群组成并升高丁酸产生。丁酸经肠肝循环上调Cxcl14表达与分泌,招募活化树突状细胞,增强CD8+ T细胞细胞毒性,抑制HCC进展。
要点
- Af6缺失增加初级胆汁酸,改变肠道菌群并升高丁酸。
- 丁酸经肠肝循环上调Cxcl14,招募活化树突状细胞增强CD8+ T细胞毒性。
- 肝细胞特异性Cxcl14过表达形成抑瘤免疫微环境,显著抑制HCC进展。
核心结论
- 肝细胞Af6缺失通过胆汁酸驱动的、菌群依赖的丁酸-CXCL14轴抑制肝癌发生。
研究设计与样本
- 建立二乙基亚硝胺诱导的Af6敲除肝癌小鼠模型,评估胆汁酸合成变化。
- 采用肝细胞特异性Af6缺失评估HCC模型的胆汁酸谱、肠道菌群组成及微生物代谢物。
- 机制研究使用小鼠及患者来源HCC类器官,并结合单细胞与bulk RNA测序。
主要发现
- Af6缺失增加初级胆汁酸水平,改变肠道菌群组成并升高丁酸产生。
- 丁酸而非胆汁酸经肠肝循环重塑肿瘤微环境,上调Cxcl14表达与分泌。
- Cxcl14招募活化树突状细胞,增强CD8+ T细胞细胞毒性。
- 肝细胞特异性Cxcl14过表达形成抑瘤免疫微环境,显著抑制HCC进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Bile acid (BA) metabolism plays an important role in the progression of liver cancer; however, the underlying mechanisms remain poorly understood. Hepatic afadin (AF6) is involved in primary BA synthesis, but its role in shaping the tumor microenvironment and immune responses in hepatocellular carcinoma (HCC) is unclear. We hypothesized that an axis involving primary BAs, butyric acid, and CXCL14 contributes to immune regulation in HCC and may inform the development of improved therapeutic strategies. METHODS: A diethylnitrosamine-induced liver cancer model with Af6 knockout was established to investigate alterations in BA synthesis. Hepatocyte-specific Af6 deficiency was used to evaluate BA profiles, gut microbiota composition, and microbial metabolites in HCC models. Mechanistic studies were conducted using murine and patient-derived HCC organoids, combined with single-cell and bulk RNA sequencing. RESULTS: Af6 deficiency increased primary BA levels, altering gut microbiota composition and elevating butyrate production. Butyrate, not BAs, reshaped the tumor microenvironment via enterohepatic circulation, upregulating Cxcl14 expression and secretion. Cxcl14 recruited activated dendritic cells, enhancing CD8+ T-cell cytotoxicity. Hepatocyte-specific Cxcl14 overexpression created a tumor-suppressive immune microenvironment, significantly inhibiting HCC progression. CONCLUSIONS: AF6 modulates primary BA synthesis, driving gut microbiota-dependent butyrate production and Cxcl14-mediated immune remodeling in HCC. This axis highlights a novel mechanism linking BA metabolism, gut microbiota, and immune regulation, offering potential therapeutic targets for liver cancer treatment. IMPACT AND IMPLICATIONS: This study establishes that hepatic Af6 deficiency restrains hepatocarcinogenesis via a bile acid (BA)-driven, microbiota-dependent butyrate-CXCL14 axis. This axis highlights a novel mechanism linking BA metabolism, gut microbiota, and immune regulation, providing potential therapeutic targets for liver cancer treatment. Notably, we describe the first mouse model in which enhanced primary BA production occurs without concomitant alterations in epithelial morphology. This model could provide a valuable platform for investigating BA-associated pathological processes in the gastrointestinal tract, including cancer progression.
引用
- Xu K, Dong X, Qu H, et al. AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC. J Hepatol. 2026. PMID: 41577299. doi:10.1016/j.jhep.2025.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。